19674 Federal Register / Vol. 77, No. 63 / Monday, April 2, 2012 / Notices 

accomplishing reinvention goals is the 

ability to periodically receive input and 

feedback from customers about the 

design and quality of the services they 

receive. 

The NLM provides significant 

services directly to the public including 

health providers, researchers, 

universities, other federal agencies, state 

and local governments, and to others 

through a range of mechanisms, 

including publications, technical 

assistance, and Web sites. These 

services are primarily focused on health 

and medical information dissemination 

activities. The purpose of this 

submission is to obtain OMB’s generic 

approval to continue to conduct 

satisfaction surveys of NLM’s 

customers. The NLM will use the 

information provided by individuals 

and institutions to identify strengths 

and weaknesses in current services and 

to make improvements where feasible. 

The ability to periodically survey NLM’s 

customers is essential to continually 

update and upgrade methods of 

providing high quality service. 

Frequency of Response: Annually or 

biennially. Affected Public: Individuals 

or households; businesses or other for 

profit; state or local governments; 

Federal agencies; non-profit institutions; 

small businesses or organizations. Type 

of Respondents: Organizations, medical 

researchers, physicians and other health 

care providers, librarians, students, and 

the general public. The annual reporting 

burden is as follows: 

Types of respondents 

Estimated 

number of 

respondents 

Estimated 

number of 

responses per 

respondent 

Average 

burden hours 

per response 

Estimated total 

annual burden 

hours 

requested 

Researchers, Physicians, Other Health Care Providers, Librarians, Students, General Public ................................................................................... 15,000 1 .150 2,250 

The annualized cost to respondents 

for each year of the generic clearance is 

estimated to be $20,670. There are no 

Capital Costs, Operating Costs, and/or 

Maintenance Costs to report. 

Request for Comments: Written 

comments and/or suggestions from the 

public and affected agencies should 

address one or more of the following 

points: (1) Evaluate whether the 

proposed collection of information is 

necessary for the proper performance of 

the function of the agency, including 

whether the information will have 

practical utility; (2) Evaluate the 

accuracy of the agency’s estimate of the 

burden of the proposed collection of 

information, including the validity of 

the methodology and assumptions used; 

(3) Enhance the quality, utility, and 

clarity of the information to be 

collected; and (4) Minimize the burden 

of the collection of information on those 

who are to respond, including the use 

of appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms of 

information technology. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the data collection plans and 

instruments, contact: David Sharlip, 

National Library of Medicine, Building 

38A, Room B2N12, 8600 Rockville Pike, 

Bethesda, MD 20894, or call non-toll 

free number 301–402–9680 or Email 

your request to sharlipd@mail.nih.gov. 

Comments Due Date: Comments 

regarding this information collection are 

best assured of having their full effect if 

received within 60 days of the date of 

this publication. 

Dated: March 27, 2012. 

David H. Sharlip, 

NLM Project Clearance Liaison, National 

Library of Medicine, National Institutes of 

Health. 

[FR Doc. 2012–7831 Filed 3–30–12; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Small 

Grants for Behavioral Research in Cancer 

Control (R03). 

Date: June 7, 2012. 

Time: 8:30 a.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Doubletree Hotel Bethesda, 8120 

Wisconsin Avenue, Bethesda, MD 20814. 

Contact Person: Ellen K Schwartz, EDD, 

MBA, Scientific Review Officer,Special 

Review & Logistics Branch, Division of 

Extramural Activities, National Cancer 

Institute, NIH, 6116 Executive Boulevard 

Room 8055B, Bethesda, MD 20892–8329, 

301–594–1215, schwarel@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Innovative 

Molecular Analysis Technologies for Cancer 

(R21). 

Date: June 26–27, 2012. 

Time: 8 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications and/or proposals. 

Place: Doubletree Hotel Bethesda, 8120 

Wisconsin Avenue, Bethesda, MD 20814. 

Contact Person: Jeffrey E. DeClue, Ph.D., 

Scientific Review Officer, Special Review 

and Logistics Branch, Division of Extramural 

Activities, National Cancer Institute, NIH, 

6116 Executive Boulevard Room 8059, 

Bethesda, MD 20892–8329, 301–496–7904, 

decluej@mail.nih.gov. 

Information is also available on the 

Institute’s/Center’s home page: http:// 

deainfo.nci.nih.gov/advisory/sep/sep.htm, 

where an agenda and any additional 

information for the meeting will be posted 

when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: March 27, 2012. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2012–7824 Filed 3–30–12; 8:45 am] 

BILLING CODE 4140–01–P 

mstockstill on DSK4VPTVN1PROD with NOTICES